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Abstract: 
Background: Adolescents with cancer experience distressing physical and psychosocial 
symptoms, especially during treatment. Fatigue and sleep disturbances commonly affect 
adolescents' quality of life, but little is known about how adolescents experience these symptoms 
during an early month of chemotherapy. This study measured fatigue, sleep disturbances, and 
quality of life in 20 adolescents over 1 month while they were receiving chemotherapy. 
Methods: Multidimensional fatigue and quality of life were measured weekly with modules from 
the PedsQL Measurement Model, and sleep disturbances were measured with the General Sleep 
Disturbance Scale. 
Results: Adolescents experienced increased severity of fatigue and sleep disturbances during the 
week after treatment. Common sleep-wake problems included daytime sleepiness, decreased 
alertness, and poor sleep quality. Fatigue and sleep-wake disturbances were related symptoms, 
and both symptoms were associated with various domains of quality of life. 
Conclusions: Fatigue and sleep-wake disturbances are significant problems for adolescents 
receiving chemotherapy and negatively affect the quality of life. Clinicians should routinely 
screen adolescent patients for fatigue and sleep disturbances and intervene to minimize their 
impact using pharmacologic and nonpharmacologic strategies. 
 
Article: 
Quality of life is an important outcome measure for patients with cancer, incorporating domains 
of physical, emotional, social, and cognitive functioning.1 For adolescents receiving cancer 
treatment, quality of life is based on their abilities to participate in usual teenage activities, 
maintain relationships with friends and family, and cope with the unpleasantness that comes with 
cancer treatment.2 Unrelieved physical symptoms, such as fatigue and sleep disturbances, have 
the potential to interfere with activities of daily living and negatively impact the quality of life. A 
clear understanding of how physical symptoms affect the quality of life of the adolescents during 
cancer therapy can assist cancer clinicians and researchers to design and implement effective 
interventions to enhance adolescents' well-being during their cancer experience. 
 
Fatigue is a common and distressing symptom reported by adolescents at various stages of the 
cancer trajectory.3–6 Studies show that cancer-related fatigue severity and distress in adolescents 
are highest in the early weeks of cancer treatment and gradually decline during and after therapy, 
and are affected by a number of factors including diagnosis, type of treatment, and treatment 
tolerance.7–10 Fatigue can be a persistent symptom for some adolescent cancer survivors as they 
mature into adults, affecting social and career outcomes.11 Posttreatment fatigue in young cancer 
survivors is associated with being female, unemployed, having symptoms of pain, depression, 
and sleeping problems, the presence of comorbidities, and risk behaviors, such as tobacco use.12–
14 
 
Sleep-wake disturbances frequently co-occur with fatigue in patients with cancer, including 
adolescents.3,15–18 These symptoms, which include difficulty falling asleep, night-time 
awakenings, and daytime sleepiness, have been described alone and as components of symptom 
clusters in adults that also include depression, pain, anxiety, depressed daytime activity, and less 
robust circadian rhythms.9,19–23 The exact nature of the relationship between fatigue and sleep-
wake disturbances, however, is not known, but pediatric oncology patients with increased 
nighttime awakenings have reported more fatigue and longer but less efficient sleep.17 More 
research is needed about how these 2 common symptoms are associated and vary over time in 
adolescents, especially during the periods of cancer treatment. 
 
As survival rates for cancer increase, attention is shifting toward better symptom management to 
reduce the morbidity of cancer treatment. This is especially critical for adolescents who 
experience cancer at one of the most dynamic times of life, who receive intense multimodality 
cancer treatments, and who are likely to be long-term cancer survivors. Unfortunately, 
adolescents are often excluded from symptom and disease-focused research owing to a number 
of challenges and barriers, creating a disparity in survival and quality-of-life improvements that 
may be seen in other age groups with higher participation in research.24,25 Adolescents receiving 
cancer therapy have a lower quality of life when compared with healthy peers, especially in 
domains that include physical complaints, compromised motor function and autonomy, and 
impaired emotional functioning and mood disturbances.26 Older children and adolescents with 
cancer were found to have more problems with anxiety, emotional distress, mood disturbances, 
and altered self-perception, resulting in lower quality of life.27,28 Specific cancer diagnoses and 
treatments are also factors that affect quality of life, with higher-risk disease and longer, more 
aggressive therapy associated with lower quality-of-life scores.29 
 
Many of the studies related to symptom management and quality of life in adolescents are 
limited by samples that combine older and younger participants, by retrospective or cross-
sectional study designs with 1 or 2 measurement points, and by symptom report data obtained 
from sources other than the adolescents themselves. To strengthen the evidence from earlier 
research, this prospective study measured fatigue, sleep-wake disturbances, and the quality of 
life in adolescents receiving first-line chemotherapy for 5 consecutive weeks using self-report. 
The aims of the study were to describe the relationship between fatigue and sleep-wake 
disturbances during 1 month of chemotherapy, to describe how the symptoms varied, and to 
determine how these symptoms affected the quality of life for these adolescents. Demographic 
and treatment factors were also explored for their effect on the symptoms of fatigue and sleep-
wake disturbances. 
 
METHODS 
Design and Setting 
This prospective descriptive and correlational study measured fatigue, sleep-wake disturbances, 
and quality of life over 1 month using self-report measures in 20 adolescents receiving first-line 
chemotherapy. The 1-month study period was chosen to measure symptom trajectories before 
and after at least 1 administration of chemotherapy. Data collection began on a day of 
chemotherapy administration and continued for 28 days, with adolescents completing weekly 
reports of fatigue, sleep-wake disturbances, and quality of life. This feasibility study was 
conducted at the University of Virginia (UVa) Health System and the Virginia Commonwealth 
University (VCU) Health System. 
 
Sample 
Participant inclusion criteria included adolescents who: (1) were age 12 to 19 years at the time of 
cancer diagnosis; (2) were receiving their second, third, fourth, or fifth month of chemotherapy; 
(3) assented to participate in the study; (4) had a parent who consented to the study if the 
adolescent was a minor; and (5) had the ability to read and write English. Patients receiving 
concurrent biotherapy or radiation therapy were not eligible. Every available adolescent who met 
the inclusion criteria at the 2 settings was invited to participate in the study. 
 
Procedures 
The study was approved by the Cancer Center Protocol Review Committees (CCPRC) and the 
Institutional Review Boards (IRB) at the 2 study sites. A Certificate of Confidentiality from the 
National Institute of Nursing Research was obtained to protect the identities of adolescents who 
chose to self-report the use of illegal substances (tobacco, alcohol, or marijuana) on the sleep 
disturbance questionnaire. Patients who were interested in the study, and their parents if they 
were minors, learned about the study and completed assent/consent procedures in the outpatient 
setting. They were given the option to complete paper or electronic versions of the instruments. 
 
Instruments 
Instruments that measure fatigue, sleep-wake disturbances, and quality of life with a 1-week 
recall were chosen for the study (Table 1). Three instruments were chosen from the PedsQL 
Measurement Model, which offers reliable and valid developmentally-designed modules to 
measure health-related quality of life and other symptoms in healthy and chronically-ill children 
and adolescents. The study used the teen self-report version of the PedsQL Multidimensional 
Fatigue Scale (MFS), developed for ages 13 to 18 years, to measure multidimensional fatigue.30 
Quality of life was measured with the PedsQL 4.0 Generic Core Scale (teen report) and the 
PedsQL 3.0 Cancer Module Acute Version (teen report) from the PedsQL Measurement Model 
System.30 In this study, the school function items were dropped from the total and psychosocial 
subscale scores of the PedsQL 4.0 Generic Core Scale because they were not applicable for 7 of 
the participants. (Three of the 19-year-old participants completed high school, but were not in 
college, and 4 of the younger teenagers were not regularly attending school because it was 
summer.) 
 
Table 1: Instruments Used to Measure Fatigue, Sleep, and Quality of Life 
Instrument Author/Year Domains (# of Items) Scoring 
Reliability in this Study 
(Cronbach α) 
PedsQL Multidimensional 
fatigue scale 
Varni et al30 General fatigue (6) 
sleep/rest fatigue (6) 
cognitive fatigue (6) 
5-point Likert scale; 
scores range from 0-100, 
and higher scores indicate 
fewer problems 
Total scale = 0.92-0.95 
general fatigue = 0.87-0.96 
cognitive fatigue = 0.89-0.95 
General sleep disturbance 
scale 
Lee31 Sleep quality (10) 
daytime function (5) 
sleep aids (6) 
8-point Likert scale for 
frequency of 0 (not at all) 
to 7 (every day); mean 
score > 3 is criteria for 
possible sleep disorder 
using DSM-IV criteria32 
Sleep quality = 0.72-0.90 
daytime function = 0.63-0.93 
PedsQL 4.0 generic core scale Varni et al30 Physical function (8) 
emotional function (5) 
social function (5) 
school function (5) 
5-point Likert scale; 
scores range from 0-100, 
and higher scores indicate 
better quality of life 
Physical function = 0.85-0.95 
psychosocial function = 0.86-0.92 
PedsQL 3.0 cancer module Varni et al30 Pain (2) 
nausea (5) 
procedural anxiety (3) 
treatment anxiety (3) 
worry (3) 
cognitive problems (5) 
perceived physical 
appearance (3)  
communication (3) 
5-point Likert scale; 
scores range from 0-100, 
and higher scores indicate 
better quality of life 
Total scale = 0.83-0.93 
 
 
The General Sleep Disturbance Scale (GSDS) was used to measure disturbances in sleep 
quantity and quality.31 The GSDS has been reliable when used to measure sleep disturbances in 
healthy young adults and women infected with human immunodeficiency virus (HIV).33–35 
Evidence for concurrent validity of the GSDS was shown through correlations with actigraphy,35 
and evidence for construct validity was shown with groups of healthy adults working rotating 
shifts.31 The sleep aids subscale of the GSDS was excluded in the analysis because all but 3 
participants reported that they did not use any sleep aids. 
 
Baseline demographic data and information about the cancer diagnosis and treatment plan were 
retrieved from the medical record at the time of participant enrollment. Ongoing treatment 
information was collected weekly during the study period. 
 
Analyses 
Descriptive statistics were calculated for demographic and instrument variables. Because of the 
small sample size and distributions that were not normal for many variables, nonparametric 
statistics were used. Weekly scores were examined for changes over the 5 weekly time points 
using graphs and the Friedman test. Correlational analyses using Spearman coefficient examined 
the relationships between the symptoms of fatigue and sleep disturbances and between each 
symptom and quality of life (generic and cancer-specific). Correlational analyses determined the 
effects of age and length of time on chemotherapy on the symptoms of fatigue and sleep-wake 
disturbances. Data were also examined for the differences in symptom severity between groups 
based on sex and diagnosis at each time point using the nonparametric Mann-Whitney U test. 
Data analyses were conducted using the Statistical Package for the Social Sciences (SPSS) 
version 15.0. 
 
RESULTS 
Thirty-two adolescents were invited to participate in the study, and 7 adolescents declined to 
participate, for a 22% refusal rate. Four patients who enrolled in the study did not complete all of 
the self-report measures (16% attrition rate). Data from 1 patient is not included because she 
received only oral chemotherapy. 
 
The convenience sample included 20 adolescents diagnosed with cancer, age 12 to 19 years 
(mean age=16.12 y, SD=2.13) (Table 2). Half of the participants were female, and most (85%) 
were White. The most common diagnoses were acute lymphoblastic leukemia (ALL) and non-
Hodgkin lymphoma. The participants' length of time since the initiation of chemotherapy to 
study entry ranged from 5 to 17 weeks (mean time on therapy=8.71 wk, SD=3.56). The group of 
adolescents was being treated with 10 different treatment regimens, specific to their cancer 
diagnosis. These regimens included intravenous (IV), intrathecal (IT), and oral chemotherapy 
agents, given every week, every 2 weeks, or every 3 weeks, and some treatments that occurred 
over several consecutive days. 
 
Table 2: Demographics of Adolescents in Study 
Variable N (20) % 
Sex   
Female 10 50 
Male 10 50 
Race   
White 17 85 
African American 3 15 
Diagnosis   
ALL 7 35 
Hodgkin lymphoma 6 30 
Non-Hodgkin lymphoma 2 10 
Sarcoma 2 10 
AML 1 5 
Rhabdomyosarcoma 1 5 
Neuroblastoma 1 5 
 
Twelve adolescents received their chemotherapy on an outpatient basis and required no 
hospitalization during the study period. Four adolescents each had 1 short unscheduled (2 to 3 d) 
hospitalization for complications, including neutropenic fevers and an allergic reaction. Four 
adolescents had scheduled hospitalizations (4 to 5 d) to receive all or part of their chemotherapy. 
 
Fatigue 
Across the 5 weeks of the study, up to 75% of adolescents reported that “feeling tired” was a 
problem “sometimes,” “often,” or “almost always” on the PedsQL MFS. Participants reported 
the least problems with cognitive fatigue and the most problems with sleep/rest fatigue (Table 3, 
Fig. 1). The highest fatigue levels (lowest scores) were reported at week 2 for the total scale, for 
the general fatigue subscale, and for the sleep/rest fatigue subscale. Changes in PedsQL MFS 
total scores were not found to be significantly different over time when examined with the 
Friedman test (P=0.82). 
 
Table 3: Means and Standard Deviations for PedsQL Multidimensional Fatigue Reports from 20 Adolescents 
Receiving Chemotherapy 
 Week 1 (Baseline)  Week 2  Week 3  Week 4  Week 5 
 Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
Total fatigue 69.45 17.30  67.56 19.55  72.17 18.71  78.30 20.10  72.45 20.02 
General fatigue 67.29 21.13  62.13 24.98  68.96 23.36  74.77 26.60  68.75 27.72 
Sleep/rest fatigue 60.67 20.38  58.11 23.43  66.42 24.16  74.07 23.11  64.58 25.28 
Cognitive fatigue 80.42 17.10  80.83 16.85  81.04 16.75  86.20 15.42  84.03 14.74 
Possible range of scores is 0-100. Higher scores indicate fewer problems with fatigue. 
 
Figure 1: Mean Values of PedsQL Multidimensional Fatigue Scores for 20 Adolescents 
Receiving Chemotherapy 
 
 
 
Sleep-wake Disturbances 
Nearly all (95%) of the adolescents recalled at least 1 sleep-wake disturbance at a frequency of 3 
days per week or more. Items approaching clinical significance based on DSM-IV criteria 
included not feeling rested (mean=3.19, SD=2.37), not feeling alert during the day (mean=3.14, 
SD=1.93), feeling sleepy during the day (mean=2.97, SD=1.96), not feeling satisfied with sleep 
quality (mean=2.93, SD=2.25), and feeling tired (mean=2.59, SD=2.07). 
Average daytime function subscale scores were higher (worse) than sleep quality subscale 
scores across all the time points (Table 4). Daytime function scores worsened from baseline to 
week 2, then improved for the next 2 time points before increasing in severity again at week 5 
(Fig. 2). Using the Friedman test, these changes in daytime function were not found to be 
significantly different over time (P=0.46). Sleep quality subscale scores improved over the first 4 
time points, before worsening again at week 5. Using the Friedman test, changes in sleep quality 
scores were not significantly different over time (P=0.41). 
 
 
Table 4: Means and Standard Deviations for GSDS Subscale Reports from 20 Adolescents Receiving 
Chemotherapy 
 Week 1 (Baseline)  Week 2  Week 3  Week 4  Week 5 
 Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
Daytime function 2.60 1.32  2.90 1.59  2.16 1.36  1.99 1.47  2.95 2.01 
Mean sleep quality 2.50 1.68  2.48 1.63  2.01 1.24  1.57 1.26  1.88 1.14 
Possible scores range from 0 to 7. Higher scores indicate more frequent sleep-wake disturbances. For example, mean of 2.6=daytime function disturbances occurred 2.6 
days in the earlier week. 
 
Figure 2: Mean values for GSDS daytime function and sleep quality scores for 20 adolescents 
receiving chemotherapy 
 
 
 
Quality of Life 
Across the 5 measurement points, scores in the physical domain of quality of life were lower 
(worse) than scores in the psychosocial domain, as measured with the PedsQL 4.0 Generic Core. 
The PedsQL 4.0 Generic Core total scale and subscale scores were lowest (worst) at week 2. For 
the PedsQL Cancer Module, scores were lowest at week 4 (Table 5). Changes in scores for the 
PedsQL Generic Core and PedsQL Cancer Module were not statistically different over time 
when examined with the Friedman test, P=0.31 and P=0.71, respectively (Figs. 3 and 4). 
 
 
Table 5: Means and Standard Deviations for PedsQL Generic Quality of Life and Cancer-related Quality of Life Reports 
from 20 Adolescents Receiving Chemotherapy 
 Week 1 (Baseline)  Week 2  Week 3  Week 4  Week 5 
 Mean SD  Mean SD  Mean SD  Mean SD  Mean SD 
PedsQL 4.0 generic core               
Total 73.19 17.78  70.37 20.42  73.13 18.67  76.23 21.29  72.80 20.98 
Physical health 63.44 23.85  60.00 26.53  62.50 26.17  68.93 27.16  61.48 29.52 
Psychosocial health 81.00 14.86  78.76 17.67  81.63 14.26  82.06 18.08  81.88 15.78 
PedsQL cancer module               
Total 76.63 12.16  75.11 15.46  78.22 13.30  78.41 16.26  72.22 17.32 
Possible scores range from 0 to 100. Higher scores indicate better quality of life. 
 
 
Figure 3: Mean Values of PedsQL Genetic Quality of Life for 20 Adolescents Receiving 
Chemotherapy 
 
 
 
Figure 4: Mean Values of PedsQL Cancer-Related Quality of Life for 20 Adolescents Receiving 
Chemotherapy 
 
 
 
Correlations Between Fatigue, Sleep-wake Disturbances, and Quality of Life 
Data at each weekly time point were explored for associations between sleep-wake disturbances 
(GSDS subscale scores of daytime function and sleep quality), fatigue (PedsQL MFS total score 
and subscale scores of general and cognitive fatigue), cancer-related QOL (PedsQL Cancer 
Module scores), and generic QOL (PedsQL 4.0 Generic Core physical and psychosocial health 
subscale summary scores) using nonparametric statistics. Items that overlapped on scales were 
excluded before each analysis. 
Table 6 lists moderately strong associations (r≥0.49, P<0.01) between pairs of variables at each 
weekly time point. At baseline, fatigue was associated with poor sleep quality and worse 
psychosocial QOL, and daytime function and sleep quality problems were associated with worse 
physical QOL. At week 1, recalling the week after chemotherapy administration, problems with 
daytime function and sleep quality were associated with worse cancer-related QOL. The final 2 
weeks showed associations between daytime function problems and worse psychosocial QOL. 
 
Table 6: Moderately Strong Correlations by Week between Fatigue, Sleep-Wake Disturbances, and Quality Life in 
20 Adolescents Receiving Chemotherapy 
Bivariate Pairs of Study Variables Week 1 (Baseline) Week 2 Week 3 Week 4 Week 5 
General fatigue and Sleep quality -0.49 — — — — 
Cognitive fatigue and Daytime function — -0.53 — — — 
Sleep quality -0.54 — — — — 
Total fatigue and Psychosocial QOL 0.51 — — — — 
Daytime function and Cancer-related QOL — -0.55 — — — 
Physical QOL _0.49 — — — — 
Psychosocial QOL — — — -0.59 -0.59 
Sleep quality and Cancer-related QOL — -0.51 -0.54 — — 
Physical QOL -0.55 — — — — 
Daytime function and sleep quality: Higher scores indicate more frequent complaints. 
Fatigue and QOL: Higher scores indicate better QOL and fewer problems. 
P<0.01 (2-tailed). –, not significant. 
 
Differences between Groups 
Data were explored at week 2 (highest symptom severity) to determine whether age and length 
of time on chemotherapy affected the symptoms of fatigue and sleep-wake disturbances. Age 
was not associated with PedsQL MFS total scores, GSDS daytime function subscale scores, or 
GSDS sleep quality subscale scores. No significant associations were found between the length 
of time on chemotherapy and PedsQL MFS total scores, GSDS daytime function subscale scores, 
or GSDS sleep quality subscale scores. 
 
Mann-Whitney U tests were used to examine differences in fatigue and sleep-wake disturbances 
between male and female adolescents and between groups based on diagnosis (leukemia and 
lymphoma versus solid tumor) at week 2. No significant sex or diagnostic group differences 
were found in fatigue severity, GSDS daytime function subscale scores, or GSDS sleep quality 
subscale scores. 
 
CONCLUSIONS 
This study explored self-reports of fatigue, sleep-wake disturbances, and quality of life from 20 
adolescents over 1 month during first-line chemotherapy. These adolescents were undergoing 
chemotherapy for the most common cancer diagnoses in this age group, including acute 
lymphoblastic leukemia, lymphoma, and sarcoma. The sample was mostly White (85%) with 
equal numbers of males and female patients, and the participants represented every age between 
12 and 19 years. The 7 patients who declined to participate were all White, both males and 
females, and significantly younger than the study sample (mean age=13.9 y, t=2.47, P<0.05). Six 
were receiving treatment for a hematologic cancer. Although their most frequent reasons for not 
participating included “not interested” and “sounds like too much work,” it is possible that the 
nonparticipants chose not to participate because of the effects of fatigue. These study results, 
therefore, may not capture the experience of younger adolescent patients who may be 
significantly limited by fatigue. 
Fatigue 
The majority of adolescents in this sample reported fatigue during the month of chemotherapy. 
Weekly scores for this adolescent sample (mean age=16 y) reflected more problems with fatigue 
than the younger children with cancer (mean age=8.72 y) but less fatigue than college-age young 
adults (mean age=20.04 y) with a variety of self-reported chronic illnesses.30,37 This finding is 
consistent with other evidence that adolescents with cancer are more bothered by fatigue than 
younger children.8,17 Possible explanations for this developmental difference include hormonal 
changes during puberty and a greater awareness and reporting of fatigue in adolescents than 
children.36 Another explanation is that the consequence of greater social and academic 
involvement for adolescents is increased fatigue.3,10 Fatigue severity in young adults with cancer 
has yet to be explored. Adolescents in this study reported fewer problems with cognitive fatigue 
(difficulty remembering, paying attention, and thinking quickly) than both the younger oncology 
sample and the sample of young adults with chronic illness.30,37 These adolescents were either 
less likely to acknowledge problems with mental fatigue or they maintained their cognitive 
ability despite complaints of generalized fatigue. 
 
The 5 weekly PedsQL MFS scores did not significantly change across the month of 
chemotherapy, but the most problems with fatigue (lowest scores) occurred after the first week, 
when the entire sample received chemotherapy. Other studies with adolescents and adults 
confirm a pattern of increased fatigue 2 to 4 days after chemotherapy.38–43 
 
Sleep-wake Disturbances 
These adolescents reported that they were frequently bothered by sleep-wake disturbances, 
especially daytime symptoms related to not feeling rested, not feeling alert, and feeling sleepy. It 
is possible that teenagers in this study did not discriminate between self-report of “sleepiness” 
and “fatigue” and that the instruments did not adequately distinguish between these 2 symptoms. 
Daytime sleepiness is defined by sleep researchers as “poor vigilance, lack of alertness, and the 
tendency to fall asleep” and is driven by an increasing sleep debt owing to insufficient sleep.44 
The National Comprehensive Cancer Network (NCCN) defines fatigue as a “sense of tiredness 
or exhaustion not proportional to recent activity.”45 Further discussion and research is needed 
about the measurement challenges related to distinguishing between the symptoms of sleepiness 
and fatigue. If sleepiness is the desired construct, measurement using an instrument specific to 
daytime sleepiness, such as the Epworth Sleepiness Scale46 or the Sleepiness Diary,47 should be 
explored. Participants in this study who reported the highest frequency of problems with daytime 
sleepiness were more likely to be female and to be in the consolidation phase of chemotherapy 
for ALL. These characteristics should be explored as contributing factors or risk factors for 
increased symptom severity. 
 
The teens' complaints of daytime sleepiness may result from an insufficient quantity of 
restorative sleep, confirmed by common responses indicating problems with difficulty falling 
asleep, getting too little sleep, waking during the night, and waking too early. Insomnia, the 
complaint of an inadequate quantity and quality of sleep, is the most common sleep-related 
problem in adults with cancer, reported to affect more than half of the population with 
cancer.48,49 Incidence and prevalence rates of cancer-related insomnia need to be described in 
adolescents, including the specific types of insomnia (eg, initiation insomnia versus maintenance 
insomnia) they experience. Many factors influence cancer-related insomnia, especially 
hospitalization and other symptoms, such as pain.6,17 The majority of adolescents in this study, 
however, were not hospitalized, and their sleep-wake disturbances reflect sleeping problems in 
their home environments. Disease-related and treatment-related factors likely add to preexisting 
lifestyle factors and biological changes in pubertal sleep that lead to disrupted sleep in 
adolescents with cancer.50–52 
 
In this study, few teenagers reported the use of prescribed and over-the-counter or other 
substances to relieve their sleep problems and chemotherapy-related side effects. It would be 
helpful to explore what strategies, if any, the adolescents use to facilitate sleep and what sleep-
promoting recommendations they receive from health care providers. 
 
Relationship between Fatigue, Sleep-wake Disturbances, and the Quality of Life 
At the time of chemotherapy administration, fatigue was associated with problems with sleep 
quality and daytime function, which in turn were associated with physical aspects of QOL. The 
association between fatigue and sleep disturbances has been established in several studies.23,53,54 
Hinds et al17 confirmed the relationship between fragmented sleep and fatigue in a sample of 
children and adolescents, suggesting a cycle in which sleep interruptions contribute to increased 
daytime fatigue, leading to longer but less efficient sleep periods. Longer periods of sleep lead to 
decreased daytime activities and disrupted sleep on subsequent nights, which over time may 
result in less robust circadian activity rhythms. Such depressed activity rhythms are considered 
an undesirable outcome and have been linked to higher fatigue levels in adults with cancer.20,55,56 
Strategies that enhance efficient sleep and help teenagers maintain robust activity patterns need 
to be explored as interventions to relieve both sleep-wake disturbances and fatigue. 
 
In the weeks after chemotherapy administration, findings suggest associations between daytime 
function, cancer-related symptoms, and psychosocial QOL and between sleep quality and 
cancer-related symptoms. On the PedsQL Cancer Module, these teenagers reported treatment-
related symptoms, such as nausea, pain, worry, and anxiety, which may have affected their 
affected sleep, mood, and interpersonal activities. Adolescents who are too tired to see friends 
and participate in the social and school activities are unlikely to feel a sense of well-being and 
satisfaction with their quality of life. Studies with adult oncology patients confirm the profound 
negative impact of fatigue and sleep-wake disturbances on health-related outcomes and quality 
of life throughout the cancer trajectory.57–59 In addition, studies have linked insufficient sleep in 
healthy adolescents with multiple negative outcomes, including poor school performance, 
behavior and mood problems, and unintentional injuries, chronic illness, and death from 
accidents.50 Co-occurring fatigue, sleep-wake disturbances, depression, and other symptoms 
need further study in adolescents with cancer, to explore common underlying physiologic 
pathways and their impact on developmental aspects of physical, emotional, and social 
performance.60,22 
 
Limitations 
This research has several limitations that need to be considered when interpreting the results. 
This study reports subjective findings from a small convenience sample of adolescents receiving 
chemotherapy without a control or a comparison group. As this sample of teenagers had a variety 
of cancer diagnoses and were receiving various chemotherapy regimens and schedules, no 
conclusions about symptom responses can be drawn about specific cancer diagnoses or 
chemotherapy regimens. The PedsQL instruments have psychometric data to support their use 
with adolescents, but self-report instruments to measure sleep-wake disturbances in adolescents 
with cancer need further development. This study provided initial evidence for acceptable 
reliability of 2 of 3 subscales (sleep quality and daytime function) of the GSDS when used with 
adolescents. 
 
Recommendations for Practice and Research 
Clinicians should not underestimate the impact of fatigue and sleep-wake disturbances on the 
quality of life of adolescents who are receiving chemotherapy. As fatigue and sleep-wake 
disturbances are so common, they should be included in routine assessments during cancer 
therapy, especially during the week of chemotherapy administration, when symptom severity is 
high. Clinicians can screen adolescent patients for fatigue severity using the numerical rating 
scale recommended in the NCCN guidelines.45 A number of screening tools are also available for 
clinicians to use to identify adolescents with sleep-wake disturbances. The “BEARS” screening 
tool is one practical guide recommended for sleep screening and assessment that includes 
questions that assess 5 major sleep domains: “B” is for bedtime problems, “E” is for excessive 
daytime sleepiness, “A” is for night-time awakenings, “R” is for regularity of sleep, and “S” is 
for sleep-disordered breathing.61 
 
Causes of fatigue and sleep disruption, whether associated with cancer treatment, hospitalization, 
or with the adolescents' lifestyle, should be identified and considered important points for 
intervention to facilitate optimal activity/rest patterns for teenagers with cancer. Scheduling 
restorative sleep during chemotherapy may play a critical role in minimizing fatigue and other 
physical and psychosocial symptoms. Clinicians need to stress the importance of optimizing 
daily periods of activity and rest and strategize with adolescents about ways to maintain regular 
schedules and involvement in developmentally critical activities despite the irregularities that 
accompany rigorous chemotherapy regimens. Clinicians may consult resources on the website of 
the Oncology Nursing Society (ONS) (http://www.ons.org/outcomes) for evidence-based 
interventions that have been evaluated to relieve fatigue and sleep-wake disturbances in adults 
with cancer. Interventions to prevent and manage fatigue and sleep-wake disturbances include a 
variety of cognitive-behavioral therapies, complementary therapies, psychoeducational and 
information interventions, energy conservation and activity management, and exercise.58,62 The 
benefits and risks of pharmacologic management of common sleep-problems in adolescents 
should also be considered.63 
 
Prospective research with both subjective and objective sleep measurement is needed with larger 
samples of adolescents to investigate the specific sleep-wake disturbances of adolescents with 
cancer, especially related to insomnia, daytime symptoms such as sleepiness and irritability, and 
daily patterns of activity and rest. Interventions that show evidence for effective symptom 
management, both pharmacologic and nonpharmacologic, are needed to decrease the symptom 
burden of fatigue and sleep-wake disturbances for adolescents during cancer chemotherapy and 
improve their quality of life. 
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